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N423K in the C4 region of gp120 was necessary for 
utilizing inhibitor-bound CCR5 receptor while the 
other gp120 mutations (R117Q, KG138-39ΔΔ, L396V) 
augmented resistance levels . Resistance to MVC and 
other CCR5 antagonists is typically associated with a 
variety of gp120 mutations but almost all are linked 
to mutations in the V3 loop, i.e. necessary for the 
resistant phenotype . In our MVC resistance selection 
experiments, a mutation at the tip of the V3 loop 
emerged in both untreated and MVC treated viral 
passages . This Q315R mutation was not associated 
with altered MVC sensitivity . Receptor affinity profiling 
using 293 Affinofile cells revealed an overall reduction 
in entry efficiency with the development of resistance . 
CONCLUSIONS: The development of resistance 
to maraviroc in a subtype A primary HIV-1 isolate 
resulted in multiple mutations throughout gp120 but 
was primarily linked to a novel N423K mutation in 
C4 region . Resistance related to the ability to utilize 
an inhibitor-bound receptor for viral entry . Unlike all 
previous studies, resistance to MVC was not associated 
with a change in the V3 loop, i.e. a region responsible 
for engagement with CCR5 . Models of X-ray crystal 
structures suggest resistance mutations are in 
approximation to the CCR5 binding site in gp120 . 
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Identification of Potential Drug 
Resistant Mutations in HIV-1 
Infected Patients with Long-term 
Undetectable Viral Load after 
Receiving HAART
H Wu, HJ Zhang, XM Zhang, QW Zhang, and BJ Zheng
Department of Microbiology, the University of Hong 
Kong, Hong Kong
BACKGROUND: This study aimed to identify potential 
drug resistant mutations in proviral DNA in HIV 
patients with long-term undetectable viral load after 
receiving HAART . 
METHOD: Peripheral blood mononuclear cells 
(PBMC) were collected from 45 patients twice per 
year from 2005 to 2009 . These patients have been 
receiving effective highly active antiretroviral therapy 
(HAART) for 3 to 13 years . The env gene (C2V5), 
protease (PR) gene and the first 400 codons of the 
reverse transcriptase (RT) gene were amplified from 
PBMC DNA, sequenced and subjected to phylogenetic 
analysis .
RESUTS: A total of 190 sequences of PR and RT and 37 
sequences of C2V5 region of env gene were amplified 
from PBMC samples of the patients . C2V5 amplification 
failed in 8 patients, while PR and RT amplification 
failed in 7 patients . According to sequencing results 
of C2V5 or PR and RT genes, 29 (70 .7%) patients were 
infected by HIV-1 AE subtype, 8 (19 .6%), 3 (7 .3%) and 
1(2 .4%) patients were infected by B and C and CRF08_
BC subtypes, respectively . Thymidine analog mutation 
(TAM) type II pattern selected by the thymidine 
analogs was detected in 5 patients who have received 
antiretroviral therapy for about 10 years . Two of these 
5 patients also developed multi-nucleoside resistance 
mutation Q151M and M184I, respectively . The most 
common NRTI resistance mutation, M184V, was found 
in two patients, including one who developed major 
protease inhibitor resistance mutation L90M . No 
any drug-resistant mutation was found in the other 
14 patients who have received CBV-based or 3TC/
ABC based treatment for 3 to 12 years . Phylogenetic 
analysis showed short genetic distances in different 
time points during treatment .
CONCLUSIONS: TAM type II pattern mutations can 
persist in provial DNA for longer than 10 years . The 
possibility of developing major resistant mutations is 
low and proviral DNA evolution is limited in patients 
with successful HAART .
